Individualized treatment of nasopharyngeal carcinoma with lung metastasis in an elderly patient: A case report

Cai,Tengteng

doi:10.3892/ol.2025.15234

Individualized treatment of nasopharyngeal carcinoma with lung metastasis in an elderly patient: A case report

Authors:
- Tengteng Cai
View Affiliations

Affiliations: Department of Radiotherapy, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, P.R. China
Published online on: August 19, 2025 https://doi.org/10.3892/ol.2025.15234
Article Number: 488
Copyright: © Cai . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is a common head and neck malignancy, particularly in southern China, with distant metastasis posing significant treatment challenges, particularly in elderly patients. This case report details the successful management of a 90‑year‑old male with NPC and lung metastasis. The patient underwent intensity‑modulated radiotherapy for the nasopharyngeal tumor (70 Gy/35 fractions) with concurrent oral capecitabine, followed by stereotactic body radiotherapy (60 Gy/12 fractions) and immunotherapy (tislelizumab) for progressive lung lesions. Maintenance therapy with capecitabine was continued and the patient achieved stable disease with minimal adverse effects. This case highlights the efficacy of individualized multimodal therapy, including precision radiotherapy, chemotherapy and immunotherapy, in an elderly patient with NPC with metastasis, offering a potential framework for similar cases.

View Figures

View References

1	Chang ET, Ye W, Zeng YX and Adami HO: The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 30:1035–1047. 2021. View Article : Google Scholar : PubMed/NCBI
2	Su ZY, Siak PY, Lwin YY and Cheah SC: Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. 43:919–939. 2024. View Article : Google Scholar : PubMed/NCBI
3	Merabishvili V: Review Cancer incidence in Five Continents Vol. XI/Ed. by F. Bray, M. Colombet, L. Mery, M. Piñeros, A. Znaor, R. Zanetti and J. Ferlay. IARC Sci. publ. № 166, Lyon, France, 1545 p. Voprosy Onkologii. 67:8552021. View Article : Google Scholar
4	Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr and Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 341:2061–2067. 1999. View Article : Google Scholar : PubMed/NCBI
5	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
6	Mukherji SK and Castillo M: Normal cross-sectional anatomy of the nasopharynx, oropharynx, and oral cavity. Neuroimaging Clin N Am. 8:211–218. 1998. View Article : Google Scholar : PubMed/NCBI
7	Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, Du XJ, Fang WF, Feng M, Gao J, et al: The Chinese society of clinical oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 41:1195–1227. 2021. View Article : Google Scholar : PubMed/NCBI
8	Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, Lee VHF, Tung SY, Chan ATC, Sze HCK, et al: Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 77:16–21. 2018. View Article : Google Scholar : PubMed/NCBI
9	Yao CY, Zhou GR, Wang LJ, Xu JH, Ye JJ, Zhang LF, He X, Chen ZZ and Huang SF: A retrospective dosimetry study of intensity-modulated radiotherapy for nasopharyngeal carcinoma: Radiation-induced brainstem injury and dose-volume analysis. Radiat Oncol. 13:1942018. View Article : Google Scholar : PubMed/NCBI
10	Qin DX, Hu YH, Yan JH, Xu GZ, Cai WM, Wu XL, Cao DX and Gu XZ: Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer. 61:1117–1124. 1988. View Article : Google Scholar : PubMed/NCBI
11	Zhou P, Zhou R, Yu YF, Rao MY and Wu SG: Xerostomia: An easily ignored symptom induced by induction chemotherapy in patients with nasopharyngeal carcinoma. Head Neck. 45:3024–3032. 2023. View Article : Google Scholar : PubMed/NCBI
12	Cao X, He LR, Xie FY, Chen YF and Wen ZS: Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: Does combined modality treatment benefit? BMC Cancer. 11:3702011. View Article : Google Scholar : PubMed/NCBI
13	Zeng L, Tian YM, Huang Y, Sun XM, Wang FH, Deng XW, Han F and Lu TX: Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: Therapeutic approaches and prognostic factors. PLoS One. 9:e1080702014. View Article : Google Scholar : PubMed/NCBI
14	Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, Sze WM, Law CK, Leung TW and Chan AT: Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal carcinoma study group. Cancer. 101:300–306. 2004. View Article : Google Scholar : PubMed/NCBI
15	Teo PM, Kwan WH, Lee WY, Leung SF and Johnson PJ: Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer. 77:2423–2431. 1996. View Article : Google Scholar : PubMed/NCBI
16	Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien R, et al: Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group ‘stereotactic radiotherapy.’. Lung Cancer. 97:51–58. 2016. View Article : Google Scholar : PubMed/NCBI
17	Yang X, Ren H, Li Z, Peng X and Fu J: Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma. Int Immunopharmacol. 125((Pt A)): 1110942023. View Article : Google Scholar : PubMed/NCBI
18	Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, Ma Y, Zhao H, Huang Y, Xue C, et al: Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 32:862015. View Article : Google Scholar : PubMed/NCBI
19	Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, et al: Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19:1338–1350. 2018. View Article : Google Scholar : PubMed/NCBI
20	Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, et al: Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. J Clin Oncol. 35:4050–4056. 2017. View Article : Google Scholar : PubMed/NCBI
21	Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al: Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An International, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 36:1412–1418. 2018. View Article : Google Scholar : PubMed/NCBI
22	Zhang R, He Y, Wei B, Lu Y, Zhang J, Zhang N, He R, Xue H and Zhu B: Nasopharyngeal carcinoma burden and its attributable risk factors in China: Estimates and forecasts from 1990 to 2050. Int J Environ Res Public Health. 20:29262023. View Article : Google Scholar : PubMed/NCBI
23	Chan WL, Chow JCH, Xu ZY, Li J, Kwong WTG, Ng WT and Lee AWM: Management of nasopharyngeal carcinoma in elderly patients. Front Oncol. 12:8106902022. View Article : Google Scholar : PubMed/NCBI
24	Huang Y, Chen W, Haque W, Verma V, Xing Y, The BS and Brian Butler E: The impact of comorbidity on overall survival in elderly nasopharyngeal carcinoma patients: A National cancer data base analysis. Cancer Med. 7:1093–1101. 2018. View Article : Google Scholar : PubMed/NCBI
25	Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
26	Piccirillo JF: Importance of comorbidity in head and neck cancer. Laryngoscope. 110:593–602. 2000. View Article : Google Scholar : PubMed/NCBI
27	Göllnitz I, Inhestern J, Wendt TG, Buentzel J, Esser D, Böger D, Mueller AH, Piesold JU, Schultze-Mosgau S, Eigendorff E, et al: Role of comorbidity on outcome of head and neck cancer: A population-based study in Thuringia, Germany. Cancer Med. 5:3260–3271. 2016. View Article : Google Scholar : PubMed/NCBI